Novo Nordisk A/S
NVOHealthcare Drug Manufacturers General
Novo Nordisk A/S’s revenue for fiscal 2025 (year ended December 2025) was $46.8 billion, up 11.1% from fiscal 2024.
- Revenue
- +3.87%
- EPS
- −17.1%
- Free cash flow
- −14.8%
- Total debt
- +30.7%
Quarter to September 2026, against a year earlier
Follow NVO
Alert me
Novo Nordisk A/S (NVO) EV/Sales
As of Nov 19, 2026, Novo Nordisk A/S (NVO) trades at a EV/Sales of 3.6×. Over the past ten years it has ranged from 3.4× (October 2026) to 18.5× (June 2024); the current reading is higher than 1% of that period. That is below the Drug Manufacturers General industry median of 4.1× and above the Healthcare sector median of 3.3×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 5.1× | (44.90%) |
| FY2024 | 9.3× | (31.06%) |
| FY2023 | 13.5× | 9.45% |
| FY2022 | 12.4× | 7.30% |
| FY2021 | 11.5× | 37.92% |
| FY2020 | 8.4× | 12.71% |
| FY2019 | 7.4× | 16.26% |
| FY2018 | 6.4× | (17.32%) |
| FY2017 | 7.7× | 46.14% |
| FY2016 | 5.3× | (42.05%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 3.5× | (21.27%) |
| Jun 2026 | 4.4× | 23.29% |
| Mar 2026 | 3.6× | (30.52%) |
| Dec 2025 | 5.1× | (6.09%) |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SNY Sanofi compare | 2.1× |
| GSK GSK PLC Sponsored ADR compare | 2.8× |
| BMY Bristol Myers Squibb Company compare | 3.0× |
| PFE Pfizer Inc. compare | 3.2× |
| NVO Novo Nordisk A/S | 3.6× |
| AZN AstraZeneca PLC compare | 4.7× |
| NVS Novartis AG compare | 5.6× |
| AMGN Amgen Inc. compare | 7.2× |
| GILD Gilead Sciences, Inc. compare | 7.3× |
| Drug Manufacturers General industry median | 4.1× |
| Healthcare sector median | 3.3× |
| Market median | 2.0× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on NVO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement